On Wednesday, AnaptysBio hit an important technical milestone, with its Relative Strength (RS) Rating climbing into the 90-plus percentile with an upgrade to 91, a rise from 75 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an RS Rating of over 80 at the beginning of a new price run.
AnaptysBio is now considered extended and out of buy range after clearing a 28.50 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company showed 0% EPS growth last quarter, while sales growth came in at 103%.
AnaptysBio earns the No. 73 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
